Small-cell lung cancer accounts for about 10%-15% of all lung cancers, yet its molecular pathogenesis remains largely unexplored due to its rapid progression and a scarcity of surgical specimens.
Simcere Zaiming Pharmaceutical Co. Ltd. has divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
Shenogen Pharma Group Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety coupled to an estrogen receptor α (ER-α; ESR1)-targeting moiety through a linker reported to be useful for the treatment of cancer, infections, immunological disorders, diabetes, inflammatory and cardiovascular disorders.
Acerand Therapeutics (Hong Kong) Ltd. has synthesized compounds acting as EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer.
S-Infinity Pharmaceuticals Co. Ltd. has disclosed azaquinoline ring-containing compounds acting as Tpl-2/Cot (MAP3K8) kinase inhibitors reported to be useful for the treatment of cancer, diabetes and inflammatory disorders.
Ubiquitin-specific proteases (USPs) play a crucial role in tumor progression, regulating the stability or functions of specific substrate proteins. USP33 expression is altered in several types of cancer, including ovarian cancer, pancreatic cancer and glioma.
Atavistik Bio Inc. has entered into a research collaboration with Pfizer Inc. to accelerate the discovery of novel precision allosteric therapeutics for unmet medical needs. Under the collaboration, Atavistik Bio will leverage its proprietary AMPS platform to identify novel allosteric binders against two undisclosed targets selected by Pfizer.
Innovent Biologics Inc. has entered into a collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd. to advance the development of IBI-3009, a novel DLL3-targeted antibody-drug conjugate (ADC) candidate.
RSS
